Clinical Trials
Category Added in a WPeMatico Campaign
-
Impact of tele-nursing on maternal self-efficacy and anxiety in post-discharge epilepsy care: an quasi-experimental study
CONCLUSION: Tele-nursing after discharge caused a significant decrease in anxiety and increased self-efficacy of mothers in taking care of their children; therefore, it is recommended to use a comprehensive program in the form of tele-nursing according to parents’ educational needs and wishes.
-
Comparison of the effect of the pulsed Er: YAG laser and topical corticosteroid on erosive oral lichen planus: a randomized clinical controlled trial
The formation mechanism of OLP is very complicated, and its treatment has always been a difficult problem. This study was to explore the feasibility of pulsed Er: YAG laser in the treatment of erosive OLP by comparing its effect with that of Triamcinolone Acetonide ointment(TA) of OLP, in order to provide new ideas for the…
-
Effect of Multi-trace Elements Supplementation on Biochemical Markers and Postoperative Outcome in Patients Undergoing Elective Cardiac Surgery
CONCLUSION: The patients undergoing CABG appeared to benefit from trace element supplementation. A brief period of Addamel administration following CABG could prevent a decrease in the serum concentration of trace elements and reduce the circulating plasma CRP.
-
A clinical trial on pelvic floor sensory testing in women with and without stress urinary incontinence
CONCLUSIONS: Women with mild stress urinary incontinence have impaired two-point discrimination ability in the pelvic floor region.
-
Personalized Alzheimer’s Risk Reduction Software Improves Calculated Alzheimer’s Risk: A Digital, Decentralized, Randomized Controlled Trial (P1-3.004)
CONCLUSIONS: RetainYourBrain effectively promotes behavior change in lifestyle domains linked to dementia risk. This innovative software offers a convenient, automated and cost-effective method for lowering AD risk that can be implemented more widely than otherwise possible in traditional, face-to-face health care encounters (ClinicalTrials.gov/NCT06027320). Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the…
-
Urologists’ Estimation of Online Support Group Utilization Behavior of Their Patients With Newly Diagnosed Nonmetastatic Prostate Cancer in Germany: Predefined Secondary Analysis of a Randomized Controlled Trial
CONCLUSIONS: Physicians are more aware of F2FGs than OSGs. Before COVID-19, F2FGs played a minor role. One out of 4 patients used OSGs. One-third considered them helpful for treatment decision-making. OSG use rarely affects the final treatment decision. Urologists significantly underestimate OSG use by their patients. Peer-to-peer support is more likely to be received by…
-
Correlation Between MG Symptoms PRO and Existing MG-Specific Outcome Scores in the Phase 3 MycarinG Study: Post Hoc Analysis (P1-11.026)
CONCLUSIONS: As expected, the five MG Symptoms PRO scales, which incorporate additional concepts such as physical fatigue, had stronger correlations with comparable concepts in MG-ADL and weaker correlations with QMG likely resulting from comparing patient- and clinician-reported data with different recall times. MG Symptoms PRO can complement existing MG-specific outcome measures to provide a granular…
-
Impact of Lemborexant on Daytime Sleepiness/Alertness in Participants With Comorbid Insomnia and Mild Obstructive Sleep Apnea (P9-4.004)
CONCLUSIONS: While the sample size was too small to detect statistical differences, a greater percentage of participants with COMISA experienced improvements in morning sleepiness across the treatment period with LEM versus PBO. These data align with previous findings that LEM does not affect tasks requiring morning alertness. Disclosure: Margaret Moline has received personal compensation for…
-
Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
CONCLUSIONS: INFRONT-3 is designed to provide evidence of efficacy and safety for latozinemab, a potential first-in-class approach for treating FTD-GRN in a representative population spanning disease severity. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Carter has received personal compensation for serving as…
-
Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results Through 24 Months From a Phase 1 Study (S37.005)
CONCLUSIONS: Bemdaneprocel demonstrated a favorable safety profile and trended toward clinical benefit or stability through 24 months post transplantation. All participants have enrolled in a continued-evaluation study (NCT05897957). These results support the ongoing development of bemdaneprocel in a Phase 3 trial to evaluate efficacy and safety in people with PD. Disclosure: The institution of Dr.…